Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.

2.
3.

[Resistance profile of rilpivirine].

Imaz A, GarcĂ­a F, di Yacovo S, Llibre JM.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:36-43. doi: 10.1016/S0213-005X(13)70141-1. Review. Spanish.

PMID:
24252532
4.

[Etravirine: genetic barrier and resistance development].

Llibre JM, Santos JR, Clotet B.

Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:32-9. doi: 10.1016/S0213-005X(09)73217-3. Review. Spanish.

PMID:
20116626
5.

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.

Boone LR.

Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. Review.

PMID:
16499282
6.

Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

Penazzato M, Giaquinto C.

Drugs. 2011 Nov 12;71(16):2131-49. doi: 10.2165/11597680-000000000-00000. Review.

PMID:
22035514
7.

Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.

Schafer JJ, Short WR.

Antivir Ther. 2012;17(8):1495-502. doi: 10.3851/IMP2254. Epub 2012 Aug 10. Review.

PMID:
22878339
8.

Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.

La Regina G, Coluccia A, Silvestri R.

Antivir Chem Chemother. 2010 Aug 11;20(6):213-37. doi: 10.3851/IMP1607. Review.

PMID:
20710063
9.

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Deeks SG.

J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33. Review.

PMID:
11264999
11.

HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Ghosn J, Chaix ML, Delaugerre C.

AIDS Rev. 2009 Jul-Sep;11(3):165-73. Review.

PMID:
19654858
12.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
13.
14.
15.

[Mechanism of action and pharmacokinetics of rilpivirine].

Portilla J, Estrada V.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:2-5. doi: 10.1016/S0213-005X(13)70136-8. Review. Spanish.

PMID:
24252527
16.

The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.

Sluis-Cremer N.

Viruses. 2014 Jul 31;6(8):2960-73. doi: 10.3390/v6082960. Review.

17.

Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):753-68. doi: 10.1089/AID.2013.0262. Epub 2014 Jul 8. Review.

18.

Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.

Dailly E, Allavena C, Deslandes G, Bouquie R, Jolliet P, Raffi F.

Curr Clin Pharmacol. 2014;9(4):399-403. Review.

PMID:
24218996
19.

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.

Garvey L, Winston A.

Expert Opin Investig Drugs. 2009 Jul;18(7):1035-41. doi: 10.1517/13543780903055056. Review.

PMID:
19548857
20.

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update.

Song Y, Fang Z, Zhan P, Liu X.

Curr Med Chem. 2014;21(3):329-55. Review.

PMID:
24164196
Items per page

Supplemental Content

Write to the Help Desk